Bristol-Myers Squibb, Kyowa Hakko Kirin To Commercialize Coniel In China

Bristol-Myers Squibb and Kyowa Hakko Kirin will commercialize Coniel, a calcium channel blocker for the treatment of hypertension and angina pectoris, in China.

AsianScientist (Nov. 5, 2013) – Bristol-Myers Squibb has entered into a licensing agreement with Kyowa Hakko Kirin Co., Ltd. for the rights to commercialize Coniel (benidipine), a calcium channel blocker for the treatment of hypertension and angina pectoris, in China.

“With cardiovascular disease a significant public health concern in China, Coniel is an important addition to the Bristol-Myers Squibb China cardiovascular portfolio, where we’ve successfully marketed Monopril and are preparing to launch Eliquis in stroke prevention in atrial fibrillation in 2015,” said Jean-Christophe Pointeau, president, Bristol-Myers Squibb China.

“This agreement builds on our existing strengths in delivering innovative medicines to patients with serious diseases, and underscores our ongoing commitment to expanding our cardiovascular business in China,” he said.

More than 230 million, or one in five, adults have cardiovascular disease in China. According to recent estimates in 2010, due to aging and population growth, the number of annual cardiovascular events in China is projected to increase by more than 50 percent between 2010 and 2030. Hypertension, or high blood pressure, is a primary risk factor for cardiovascular disease.


Source: Bristol-Myers Squibb.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist